Novo Nordisk Exits Inflammation R&D To Focus More On Diabetes, Obesity
This article was originally published in The Pink Sheet Daily
Executive Summary
Danish insulin maker’s decision triggered by failure of its most advanced compound, anti-IL-20, for the treatment of rheumatoid arthritis.